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Originally identified as a B-cell marker, expression of the cell surface molecule CD24 has meanwhile been observed in a variety of
human malignancies. It appears to function as a ligand of P-Selectin, an adhesion molecule that is present in activated platelets and
endothelial cells. We aimed to determine the rate of CD24 expression in our nonsmall cell lung cancer (NSCLC) collection and to
clarify its correlation with clinicopathological parameters including patients’ survival. A total of 89 NSCLC were analysed
immunohistochemically using a monoclonal CD24 antibody (clone 24C02) and a standard detection system (LSAB, DAKO) on
NSCLC tissue microarrays (TMA). The staining was semiquantitatively scored (0, 1+, 2+, 3+) and grouped into high (2+, 3+)- and
low (0, 1+)-level expression for statistical analysis. A high level of CD24 expression was observed in 45% of the cases, preferentially
adenocarcinomas. Patients whose tumours had a high CD24 expression showed a significantly shorter median survival time of 23
months vs 38 months (P¼0.033, log-rank test). Similarly tumour, grading, nodal status and clinical stage were significant prognostic
markers in univariate survival analysis. Importantly, in the Cox regression-based multivariate analysis, CD24 expression (P¼0.025)
together with tumour stage (P¼0.006) and grade (P¼0.011) proved to be independent prognostic parameters. We hypothesise
that the decreased survival of NSCLC patients with strongly CD24-positive tumours is related to an enhanced propensity of
haematogenous metastasis formation, which might be P-Selectin mediated.
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Lung cancer is a major cause of death from neoplastic malignancy
in the Western world. In the USA alone, 169400 new cases are
expected for the year 2002 with 154900 expected deaths from this
disease (Jemal et al, 2002). In the last 20 years, the mortality rate
could be lowered only by 6% because of improved therapies. So
far, the most promising approach appears to be primary and
secondary prevention (Henschke et al, 1999).
The molecular biology of nonsmall cell lung cancer (NSCLC),
the largest lung cancer subgroup, is under intense international
investigation in order to characterise new molecular marker genes
which might be helpful in diagnosis or therapy. A gene that
recently has gained new interest is CD24. It is a small heavily
glycosylated mucin-like glycosyl-phosphatidylinositol(GPI)-linked
cell surface protein (Pirruccello and Le Bien, 1986; Fischer et al,
1990; Akashi et al, 1994), which is physiologically expressed not
only in developing (Shirasawa et al, 1993; Poncet et al, 1996; Cram
et al, 1999) or regenerating (Figarella-Branger et al, 1993) tissue,
but also in granulocytes, pre-B-cells, keratinocytes (Redondo et al,
1998) and renal tubules (Droz et al, 1990). In neoplasia, CD24
expression has been described not only in haematologic malig-
nancies (Pirruccello and Lang, 1990; Raife et al, 1994; Lavabre-
Bertrand et al, 1994), but also in a large variety of solid tumours,
for example, renal cell carcinoma (Droz et al, 1990), small cell lung
cancer (Jackson et al, 1992), nasopharyngeal carcinoma (Karran
et al, 1995), hepatocellular carcinoma (Huang and Hsu, 1995),
bladder carcinoma (Gromova et al, 1999), glioma (Senner et al,
1999), breast cancer (Fogel et al, 1999; Yang et al, 1999; Liu and
Vadgama, 2000) and ovarian cancer (Welsh et al, 2001; Kristiansen
et al, 2002). CD24 is a ligand of P-selectin (Sammar et al, 1994), an
adhesion receptor on activated endothelial cells and platelets, and
could thus contribute to the metastasising capacities of CD24-
expressing tumour cells (Aigner et al, 1995, 1997, 1998; Friederichs
et al, 2000). Recently, we described CD24 as an independent
prognostic marker of shortened patient survival in ovarian cancer
(Kristiansen et al, 2002). To date very little is known about CD24
in NSCLC.
The aim of this study was to evaluate the status of CD24
expresssion in our set of NSCLC patients and to investigate the
association of CD24-protein expression determined by immuno-
histochemistry with clinicopathological parameters, disease stage
according to UICC and patient survival.
MATERIALS AND METHODS
Tumour samples
Our collective consisted of 89 patients between age 34 and 80 years
(mean 62) who underwent thoracotomy for resection of NSCLC in
the Department of Surgery at the Charite ´ University Hospital from
1995 to 1997, and whose clinical follow-up data were available. No
adjuvant radiotherapy or chemotherapy was applied before
surgery. Table 1 summarises the clinicopathological characteristics
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1997). The histopathological diagnosis was established in every
case according to the WHO guidelines (Travis, 1999). Only
primary carcinomas were included in the study.
Tissue array generation
A tissue microarray (TMA) was constructed as previously
described (Kristiansen et al, 2001). Briefly, suitable areas for
tissue retrieval were marked on standard haematoxylin–eosin
(HE) sections, punched out of the paraffin block and inserted into
a recipient block. The tissue arrayer was purchased from Beecher
Instruments (Woodland, USA). The punch diameter was 0.6mm.
The lung tumour array consisted of 127 tissue samples: 89 tumours
and 38 punches of normal or peritumoural lung tissue. For
comparison of the tissue array immunostaining with conventional
slides, whole mount paraffin sections were cut from 15 cases that
were incorporated in the tissue array.
Cell lines and primary cell culture
Four primary tumour cell lines of lung adenocarcinomas were
established in our laboratory derived from patients with primary
cancers who had surgery for NSCLC at the Charite ´ University
Hospital (D51, D54, D97, D117). These cells were grown in
Leibovitz 15 media supplemented with 10% FCS and 1%
glutamine. Small cell lung cancer cell lines (H526, H378, DMS-
79, SHP-77) and the lung squamous cell cancer cell line H2170
were purchased from the ATCC (Rockville, MD, USA). Lung
adenocarcinoma cell lines A427 and A549 were purchased from the
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). All cells were grown as recommended.
The cell lines were centrifuged and the pellets were formalin fixed
and embedded in 0.8% agarose. These agarose pellets were
finally paraffinised and conventionally sectioned for immunohis-
tochemistry.
Immunohistochemistry
The tissue array block was freshly cut (4mm), sections were
mounted on superfrost slides (Menzel-Gla ¨ser, Germany) and
dewaxed with xylene, and gradually hydrated. Antigen retrieval
was achieved by pressure cooking in 0.01 M citrate buffer for 5min.
The primary CD24-antibody (Ab-2, clone 24C02, Neomarkers,
USA) was diluted 1:100 using a background reducing dilution
buffer from DAKO (Germany). No other blocking agents were
employed. The primary antibody was incubated at room
temperature for 1h. Detection took place by the conventional
labelled-streptavidin–biotin (LSAB-kit, DAKO, Germany) method
with alkaline phosphatase as the reporting enzyme according to
the manufacturer’s instructions. Fast-Red (Sigma-chemicals,
Hamburg) served as chromogen, afterwards the slides were briefly
counterstained with haematoxylin and aquaeously mounted.
The CD24 staining was independently examined by two clinical
pathologists (GK, YY). The staining intensity was semiquantita-
tively scored from absent to strong (0, 1+, 2+, 3+) for each case.
Two TMA were processed to reduce case dropout.
Statistical analysis
Fishers exact test, which is especially suited for small sets of data,
was used to determine the strength of association between the
investigated parameters. To compare the expression of CD24 with
clinicopathological parameters, 2 2 contingency tables (e.g. CD24
score 0–1 vs 2–3 and G1& G2 vs G3) were set up and the P-values
were calculated. Cumulative survival curves were calculated
according to the Kaplan–Meier method, differences in survival
time were assessed with the log-rank test. Multivariate survival
analysis was performed on all parameters that were found to be
significant on univariate analysis using the Cox regression model.
P-values o0.05 were considered significant. All calculations were
performed using the statistical software package SPSS, version
10.0.
RESULTS
Immunohistochemistry
Of the 11 lung cancer cell lines, we observed a strong
membraneous CD24 expression in the adenocarcinoma cell line
D51 (Figure 1A). Four cell lines had a cytoplasmic staining, which
was less pronounced (A427: ADC cell line; H378, DSM-79: small
cell lung cancer cell lines; H2170: SCC cell line). Six cell lines were
negative.
Normal lung parenchyma showed a strong membraneous
staining pattern of pneumocytes (Figure 1B), whereas bronchial
epithelium was mostly negative. In tumour tissue of primary lung
carcinomas, CD24 immunoreactivity was observed in 68 (76%)
cases with a cytoplasmic and membraneous staining pattern. The
gross slides generally showed a homogenous staining of the
tumours, which is a necessary condition to obtain reliable data
from small tissue array punches. Specifically, on direct comparison
of intensity grades of conventional whole mount sections and
arrayed tissue of the same case (n¼15), we found eight identical
gradings, six cases were slightly different, but still fell into the same
group (0–1¼low-level expression vs 2–3¼high-level expression),
only a single case was discordant. This demonstrates that the CD24
staining of the tissue punch is representative (P¼0.001, Fishers
exact test).
The TMAs allowed for evaluation of 89 cases. In all, 21 cases
(24%) exhibited no relevant CD24 staining (Figure 1C). In 28 cases
(31%), a minimal staining was observed. A total of 21 cases (24%)
showed a moderate staining intensity (Figure 1D) and 19 cases
(21%) had a strong staining signal (Figure 1E, F). Taking groups
three and four together, 45% of tumours showed a high level of
expression of CD24 in this study (Table 1). This was opposed to no
or minimal CD24 expression (0, 1+) in the statistical analysis.
Statistical analysis
CD24 expression was significantly higher in adenocarcinomas
(Table 1, Fishers exact test, P¼0.001). No correlation was found
Table 1 Relationship between CD24 expression and various clinico-
pathological parameters
Characteristics Sum CD24 low CD24 high P-value
Total no. 89 49 40
Adeno 49 19 30 0.001
SCC 40 30 10
G1/G2
a 47 26 21 1
G3 42 23 19
pT1 22 12 10 1
pT2+
b 67 37 30
pN0 53 33 20 0.129
pN1+
c 36 16 20
Stage I–II
d 62 36 26 0.488
Stage III
d 27 13 14
aG1 (n=3), G2 (n=44).
bpT2 (n=57), pT3 (n=8), pT4 (n=2).
cpN1 (n=12), pN2
(n=23), pN3 (n=1).
dStages I (n=49), II (n=13), III (n=27).
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(P¼0.129) or disease stage according to UICC (P¼0.488).
Univariate survival analysis Cumulative survival curves were
calculated according to the Kaplan–Meier method, differences in
survival were assessed with the log-rank test (Table 2). First, we
analysed conventional and well-described clinicopathological
parameters. Kaplan–Meier curves demonstrated a significant
impact of tumour grading (P¼0.001), nodal status (P¼0.0001)
and tumour stage (P¼0.0005) on patient survival (Figures 2A–C).
Tumour size (pT1 vs pT2+) was of borderline significance
(P¼0.083). Histological tumour type did not show a significant
impact on patient survival time (P¼0.566), although the mean
and median survival times of squamous cell carcinomas were
shorter.
For CD24 expression, we found a statistically significant
difference of median survival time for tumours with low
levels (0, 1+) compared to tumours with high levels (2+, 3+) of
CD24 expression (Figure 2D) with 23 months vs 38 months
(P¼0.033).
Multivariate survival analysis A multivariate progression analy-
sis based on the Cox proportional hazard model was performed to
test the independent value of each parameter predicting overall
survival (Table 3). In this analysis, we included tumour grading
(G1 and G2 vs G3), disease stage (I–II vs III–IV) and CD24
expression (0, 1+ vs 2+, 3+). All three parameters, tumour grading
(P¼0.011), disease stage (P¼0.006) and CD24 expression
(P¼0.024) proved to be independent prognostic factors for
shortened overall survival in NSCLC.
Figure 1 CD24 immunohistochemistry (A–F) in NSCLC. (A) Adenocarcinoma cell line with strong membraneously accentuated CD24 expression. (B)
Normal lung parenchyma: membraneous expression in pneumocytes. (C) Normal lung parenchyma (on the left) with infiltrates of a poorly differentiated
adenocarcinoma without CD24 expression (on the right). (D) Adenocarcinoma with moderate CD24 expression (2+). (E) Adenocarcinoma and (F)
Squamous cell carcinoma with high CD24 expression (3+).
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yDISCUSSION
In this study, 11 lung cancer cell lines and tissue of 89 NSCLC cases
were immunohistologically examined for the expression of CD24
protein using a well-characterised monoclonal antibody. We found
CD24 expression in 45% (five out of 11) of the cell lines: two
adenocarcinoma cell lines (two out of six), two small cell lung
cancer cell lines (two out of four) and one squamous cell cancer
Table 2 Univariate survival analysis (Kaplan–Meier)
Characteristic
No. of
cases
Mean survival
time (months7s.e.)
Median survival time
(months7s.e.) P-value
Histology
Adeno 49 39743 6 710 0.566
SCC 40 32733 0 74
Grading
G1&2 47 45744 6 0.001
G3 42 24731 9 73#
Tumour size (pT)
pT1 22 4775 n.r.
a 0.083
pT2+ 67 32733 0 74
Nodal status
PN0 53 4574 n.r. 0.0001
PN1+ 36 22731 8 73
Stage
I–II 62 44734 6 0.0005
III 27 21731 7 75
CD24 expression
Low 49 40733 8 0.033
High 40 31742 3 73
an.r.=not reached.
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Figure 2 Survival analysis. Kaplan–Meier curves (A–D): (A) tumour grading (P¼0.001); (B) nodal status (P¼0.0001); (C) disease stage (P¼0.0005);
(D) CD24 expression (P¼0.033).
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Jackson et al, who reported CD24 expression in SCLC cell lines and
in some adenocarcinoma cell lines, although unfortunately no
details were given for the NSCLC cell lines investigated (Jackson
et al, 1992). We found a higher incidence of CD24 expression (76%
of cases) in NSCLC tissue. These different incidences of CD24
expression in cell lines and tissues might be explained in several
ways. First, CD24-positive NSCLCs might be more difficult to
culture as cell lines than CD24-negative tumours. Second, CD24
staining in tissue sections was often accentuated at cell–cell
contacts, which are mostly missing in cell lines.
To our knowledge, this is the first study to examine the CD24
expression in a larger tumour sample of NSCLC. Methodologically,
the usage of TMAs was very convenient to help processing a large
set of cases. The validity of this approach was confirmed by
comparison of the CD24 array staining results with matching
conventional whole mount sections.
We found CD24 expression to be an independent predictor of
shortened patient survival as evidenced by univariate and multi-
variate analyses in NSCLC. This raises the question of the
biological function of CD24 in NSCLC. CD24 is expressed in a
large variety of human tissues: physiologically, in developing or
regenerating tissues (Figarella-Branger et al, 1993; Shirasawa et al,
1993; Poncet et al, 1996; Cram et al, 1999) and a few mature cell
types such as, for example, granulocytes, keratinocytes (Redondo
et al, 1998) and renal tubules (Droz et al, 1990). Pathologically,
CD24 has been described in B-cell neoplasia (Pirucello and Lang,
1990; Raife et al, 1994; Lavabre-Bertrand et al, 1994), renal cell
carcinoma (Droz et al, 1990), small cell lung cancer (Jackson et al,
1992), nasopharyngeal carcinoma (Karran et al, 1995), hepatocel-
lular carcinoma (Huang and Hsu, 1995), bladder carcinoma
(Gromova et al, 1999), glioma (Senner et al, 1999), breast cancer
(Fogel et al, 1999; Liu and Vadgama, 2000) and ovarian cancer
(Welsh et al, 2001; Kristiansen et al, 2002). This ubiquitous
expression obviously excludes a diagnostic use of CD24 as a
specific marker for NSCLC or any other tumour type.
CD24 has been identified as a ligand to P-selectin (Sammar et al,
1994), and it is conceivable that this function contributes to a more
aggressive metastatic behaviour of CD24-positive tumour cells, as
in vitro evidence suggests (Aigner et al, 1995, 1997, 1998;
Friederichs et al, 2000). P-selectin is a surface molecule expressed
by activated endothelial cells and platelets (McEver, 1991). It plays
an important role in marginal adhesion and migration of cells
under shear forces in the blood stream. Moreover, P-selectin
deficiency has been linked to decreased rates of metastasis
formation in mice, which underscores the relevance of this
adhesion receptor in tumor progression (Kim et al, 1998).
Physiologically, its primary ligand is P-Selectin Glycoprotein
Ligand-1 (PSGL-1), which is expressed, for example, by neutro-
phils. Possibly, CD24-expressing tumour cells can spread more
easily because of their capacity to either form thrombi with
activated platelets or to adhere to endothelia in the bloodstream as
demonstrated for CD24-expressing breast cancer cells (Aigner et al,
1997). This mechanism of metastasis does not only require
expression of CD24 of the tumour, but also expression of P-
selectin in platelets and endothelia of the vasculature of the target
organs. Obviously, P-selectin expression on platelets and endothe-
lia of lung cancer patients can hardly be studied comprehensively
in vivo. Importantly, P-selectin-mediated binding of SCLC to
endothelial cells has already been shown in vitro (Pottratz et al,
1996) and the CD24/P-selectin pathway was found to initiate lung
colonisation of the human lung adenocarcinoma cell line A125 in a
mouse model (Friederichs et al, 2000).
These observations are consistent with the view that CD24 is a
cell surface protein that might be important for haematogenous
metastasis formation, and we feel that this is the most likely
explanation of the decreased survival times of strongly CD24-
expressing tumours because most lung cancer patients die from
systemic metastatic disease. In our study, clinicopathological
parameters were only considered at the time of surgery. Thus, we
did not find an association of CD24 with clinical stage since
patients with haematogenous metastases are excluded from
surgical therapy and are consequently not represented in our
tumour sample. Also, the nonsignificant association of CD24
expression with nodal status is compatible with this interpretation,
since lymphatic spread is a biologically different process, although
it frequently precedes haematogenous dissemination.
This study establishes CD24 expression as an independent
prognostic tumour marker in NSCLC. Our recent description of
CD24 expression as an independent marker of shortened patient
survival in epithelial ovarian cancer (Kristiansen et al, 2002)
further underscores the importance of CD24 in metastatic disease
progression of human carcinomas. Prospectively, CD24 might aid
the clinician in the selection of an appropriate therapy for
individual patients. In this circumstance, it is of relevance to
know that the intravenous administration of CD24-specific
antibodies has been sucessfully used therapeutically to treat
transplantation-associated B-cell proliferative syndrome (Fischer
et al, 1991; Garnier et al, 2002). This new therapeutic option might
deserve consideration in NSCLC patients as well.
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